BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Delivers a Better-Than-Expected Quarter

… Chief Medical Officer, referring to the positive study results for BCX4430 Delayed Treatment of Ebola Virus Infection in a Non-Human Primate Model. Full Article http://j.gs/5sTq

Click here to read full article